Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-493 and ABT-530 Dose Ranging in Genotype 1 HCV
NCT01995071Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2013
- Primary completion
- Jun 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Nov 2013; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01995071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01995071.